Skip to main content
Equibles
TELO logo

TELO · Telomir Pharmaceuticals, Inc. · Metrics

Track TELO — free

Use TELO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TELO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.24 +0.06 (+5.08%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the issuance date of this Report.”
View the 10-Q filed Aug 13, 2026
Market Cap
$84.59M
Shares
68.77M
Volume · Oct 5 134.38K Avg daily vol (3M) 75.87K

TELO metrics

47 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.18
Market cap
$84.59M

Price action

20 metrics
Price change (1W)
-4.1%
Price change (30D)
-0.8%
Price change (3M)
-7.1%
Price change (6M)
-7.1%
Price change (YTD)
-11.3%
Price change (1Y)
-15.1%
Trailing year
Price change (5Y)
—
52-week high
$1.93
52-week low
$0.92
Change from 52-week high
-38.9%
Change from 52-week low
+28.4%
Annualized volatility
74.0%
Annualized volatility (3M)
72.4%
Beta
1.8
RSI (14D)
49.6
Price vs SMA 50
+1.0%
Price vs SMA 200
-6.1%
Avg volume (3M)
75,869
Relative volume
1.0
Average dollar volume
$87,574

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
68.77M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
16.8
reciprocal yield 6.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
−$5.88M
Trailing 12 months
Diluted EPS (TTM)
$-0.91
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.17

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+102.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-116.7%
Return on assets
-109.5%
Debt / equity
—
Current ratio
16.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
16.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$754,323
Latest balance sheet
Cash & equivalents
$754,323
Total assets
$5.37M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.91M
Capital expenditures (TTM)
—
R&D (TTM)
$2.97M
SG&A (TTM)
—
Stock compensation (TTM)
$3.95M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
33
13F filer change QoQ
+6
Institutional ownership
4.3%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 19.7 days to cover
Days to cover
19.7d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1971532 CUSIP 87975F104 13F (30d) 1 filings 1 filers Visit website